Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 20 | 2024 | 1435 | 2.100 |
Why?
|
| Hypoglycemic Agents | 12 | 2022 | 620 | 0.940 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2023 | 850 | 0.890 |
Why?
|
| Insulin Resistance | 5 | 2021 | 748 | 0.850 |
Why?
|
| Blood Glucose | 15 | 2024 | 1286 | 0.700 |
Why?
|
| Hypoglycemia | 4 | 2022 | 220 | 0.640 |
Why?
|
| Metformin | 4 | 2020 | 395 | 0.630 |
Why?
|
| Hyperglycemia | 4 | 2022 | 350 | 0.610 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 813 | 0.460 |
Why?
|
| Insulin | 7 | 2022 | 1508 | 0.420 |
Why?
|
| Adolescent | 23 | 2024 | 32730 | 0.280 |
Why?
|
| Medication Adherence | 3 | 2020 | 520 | 0.270 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 1060 | 0.260 |
Why?
|
| Circadian Rhythm | 1 | 2024 | 331 | 0.200 |
Why?
|
| Puberty | 1 | 2021 | 100 | 0.190 |
Why?
|
| Sleep | 1 | 2024 | 443 | 0.180 |
Why?
|
| Wearable Electronic Devices | 1 | 2022 | 116 | 0.180 |
Why?
|
| Self Report | 1 | 2024 | 796 | 0.170 |
Why?
|
| Child | 18 | 2022 | 30559 | 0.160 |
Why?
|
| Menstruation Disturbances | 1 | 2018 | 22 | 0.160 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 188 | 0.160 |
Why?
|
| Age of Onset | 1 | 2020 | 855 | 0.150 |
Why?
|
| Insurance Coverage | 1 | 2020 | 274 | 0.150 |
Why?
|
| Medicaid | 1 | 2020 | 307 | 0.150 |
Why?
|
| Insulin Infusion Systems | 3 | 2022 | 60 | 0.130 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 319 | 0.130 |
Why?
|
| Glucagon | 1 | 2016 | 201 | 0.130 |
Why?
|
| Quality of Life | 2 | 2011 | 4755 | 0.130 |
Why?
|
| Diabetic Nephropathies | 1 | 2017 | 184 | 0.130 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 118 | 0.120 |
Why?
|
| Humans | 31 | 2024 | 272087 | 0.120 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2014 | 17 | 0.120 |
Why?
|
| Depression | 4 | 2016 | 1737 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1076 | 0.110 |
Why?
|
| Diabetic Angiopathies | 1 | 2014 | 81 | 0.110 |
Why?
|
| Family | 2 | 2009 | 779 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2020 | 9500 | 0.100 |
Why?
|
| Biomarkers | 2 | 2024 | 5115 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 374 | 0.100 |
Why?
|
| Heart Atria | 1 | 2014 | 357 | 0.100 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2023 | 117 | 0.090 |
Why?
|
| Risk Factors | 6 | 2024 | 18051 | 0.090 |
Why?
|
| Self Care | 2 | 2009 | 243 | 0.090 |
Why?
|
| Male | 18 | 2024 | 129088 | 0.090 |
Why?
|
| Young Adult | 4 | 2024 | 22142 | 0.090 |
Why?
|
| Cysteine | 1 | 2010 | 214 | 0.080 |
Why?
|
| Body Mass Index | 4 | 2021 | 2259 | 0.080 |
Why?
|
| Female | 19 | 2024 | 149288 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2014 | 847 | 0.080 |
Why?
|
| Autoantibodies | 2 | 2023 | 600 | 0.080 |
Why?
|
| Glutathione | 1 | 2010 | 376 | 0.080 |
Why?
|
| Glycine | 1 | 2010 | 319 | 0.080 |
Why?
|
| Parents | 1 | 2015 | 1072 | 0.070 |
Why?
|
| Urban Health Services | 1 | 2007 | 34 | 0.070 |
Why?
|
| Obesity, Morbid | 1 | 2010 | 238 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2009 | 266 | 0.070 |
Why?
|
| Obesity | 3 | 2015 | 2958 | 0.070 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 2307 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2011 | 682 | 0.070 |
Why?
|
| Glucose | 2 | 2023 | 1246 | 0.070 |
Why?
|
| Pregnancy, Multiple | 1 | 2006 | 48 | 0.070 |
Why?
|
| Magnesium Sulfate | 1 | 2006 | 55 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2020 | 2867 | 0.070 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2006 | 82 | 0.070 |
Why?
|
| United States | 2 | 2020 | 16066 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2009 | 2903 | 0.060 |
Why?
|
| Adult | 6 | 2024 | 81933 | 0.060 |
Why?
|
| Health Promotion | 1 | 2007 | 510 | 0.050 |
Why?
|
| Insulin, Regular, Human | 1 | 2022 | 12 | 0.050 |
Why?
|
| Health Behavior | 1 | 2007 | 602 | 0.050 |
Why?
|
| Accelerometry | 1 | 2022 | 65 | 0.050 |
Why?
|
| Social Support | 1 | 2005 | 590 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2024 | 316 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2021 | 241 | 0.040 |
Why?
|
| Child, Preschool | 4 | 2022 | 17056 | 0.040 |
Why?
|
| Exercise | 1 | 2007 | 1214 | 0.040 |
Why?
|
| Diet | 1 | 2007 | 1489 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 4400 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2021 | 244 | 0.040 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2018 | 44 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 148 | 0.040 |
Why?
|
| Time Factors | 2 | 2024 | 13139 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 358 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 405 | 0.030 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 379 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2022 | 1196 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2020 | 1622 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 344 | 0.030 |
Why?
|
| Binge-Eating Disorder | 1 | 2015 | 6 | 0.030 |
Why?
|
| Androgens | 1 | 2018 | 553 | 0.030 |
Why?
|
| Life Style | 1 | 2018 | 623 | 0.030 |
Why?
|
| Estradiol | 1 | 2018 | 881 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2021 | 13410 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 606 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 746 | 0.030 |
Why?
|
| Prevalence | 2 | 2015 | 3427 | 0.030 |
Why?
|
| Atrial Function, Left | 1 | 2014 | 28 | 0.030 |
Why?
|
| Ventricular Dysfunction | 1 | 2014 | 34 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 15279 | 0.030 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 115 | 0.030 |
Why?
|
| Testosterone | 1 | 2018 | 735 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2369 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1264 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 665 | 0.020 |
Why?
|
| Gastrointestinal Hormones | 1 | 2010 | 26 | 0.020 |
Why?
|
| Body Weight | 1 | 2015 | 1335 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2010 | 92 | 0.020 |
Why?
|
| Bariatric Surgery | 1 | 2010 | 124 | 0.020 |
Why?
|
| Asparaginase | 1 | 2009 | 186 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2010 | 257 | 0.020 |
Why?
|
| Age Factors | 2 | 2011 | 5526 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2009 | 314 | 0.020 |
Why?
|
| Echocardiography | 1 | 2014 | 1241 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 5107 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2007 | 54 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 5196 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2009 | 239 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2007 | 104 | 0.020 |
Why?
|
| Maternal Behavior | 1 | 2007 | 71 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2010 | 560 | 0.020 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2010 | 263 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 6911 | 0.020 |
Why?
|
| Magnesium | 1 | 2006 | 172 | 0.020 |
Why?
|
| Community Health Services | 1 | 2007 | 129 | 0.020 |
Why?
|
| Calcitriol | 1 | 2006 | 146 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 1036 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2006 | 217 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2021 | 39831 | 0.020 |
Why?
|
| Urban Population | 1 | 2007 | 281 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 2208 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 348 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2009 | 622 | 0.020 |
Why?
|
| Hypertension | 1 | 2015 | 1624 | 0.020 |
Why?
|
| Health Education | 1 | 2007 | 304 | 0.020 |
Why?
|
| Minority Groups | 1 | 2007 | 321 | 0.020 |
Why?
|
| Vincristine | 1 | 2009 | 1572 | 0.020 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2010 | 441 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2007 | 612 | 0.010 |
Why?
|
| Bone Density Conservation Agents | 1 | 2006 | 205 | 0.010 |
Why?
|
| Texas | 2 | 2007 | 6440 | 0.010 |
Why?
|
| Survival Rate | 1 | 2017 | 12534 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2009 | 1497 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2003 | 68 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2006 | 613 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2010 | 887 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2009 | 1310 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 3645 | 0.010 |
Why?
|
| Psychometrics | 1 | 2007 | 964 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 1994 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 22555 | 0.010 |
Why?
|
| Medical Records | 1 | 2003 | 447 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2015 | 33909 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2006 | 828 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 1594 | 0.010 |
Why?
|
| Middle Aged | 2 | 2021 | 90460 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 1232 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 73517 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2010 | 5693 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 5935 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 4900 | 0.010 |
Why?
|
| Pregnancy | 1 | 2006 | 8105 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2006 | 8612 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 10365 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 14653 | 0.000 |
Why?
|